KALV - KalVista Pharmaceuticals Inc Stock Price, Fair Value and News

$14.63+1.11 (+8.21%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KALV Price Action

Last 7 days

3.8%

Last 30 days

35.5%

Last 90 days

-3.7%

Trailing 12 Months

50.4%

KALV RSI Chart

KALV Valuation

Market Cap

739.5M

Price/Earnings (Trailing)

-3.56

Price/Sales (Trailing)

43.38

EV/EBITDA

-2.48

Price/Free Cashflow

-4.49

KALV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KALV Fundamentals

KALV Revenue

Revenue (TTM)

12.7M

KALV Earnings

Earnings (TTM)

-208.0M

Earnings Growth (Yr)

-48.59%

Earnings Growth (Qtr)

-15.07%

KALV Profitability

EBT Margin

-1418.85%

Return on Equity

-1.2K%

Return on Assets

-61.19%

Free Cashflow Yield

-22.27%

KALV Investor Care

Shares Dilution (1Y)

16.81%

Diluted EPS (TTM)

-3.96

KALV Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	0	0
2020	11.8M	12.7M	0	0
2019	18.0M	16.1M	15.8M	14.1M
2018	3.7M	8.4M	12.0M	16.5M
2017	1.6M	1.5M	655.0K	1.6M
2016	0	2.1M	1.9M	1.7M
2015	916.5K	1.8M	0	0
2014	318.5K	222.0K	125.5K	29.0K
2013	0	0	0	415.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

CEO	Mr. Thomas Andrew Crockett M.B.A.
WEBSITE	kalvista.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	118

KalVista Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for KalVista Pharmaceuticals Inc? What does KALV stand for in stocks?

KALV is the stock ticker symbol of KalVista Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of KalVista Pharmaceuticals Inc (KALV)?

As of Wed Dec 03 2025, market cap of KalVista Pharmaceuticals Inc is 739.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KALV stock?

You can check KALV's fair value in chart for subscribers.

Is KalVista Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether KALV is over valued or under valued. Whether KalVista Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact KalVista Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KALV.

What is KalVista Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, KALV's PE ratio (Price to Earnings) is -3.56 and Price to Sales (PS) ratio is 43.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on KalVista Pharmaceuticals Inc's stock?

In the past 10 years, KalVista Pharmaceuticals Inc has provided -0.116 (multiply by 100 for percentage) rate of return.